Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BeNeBio dose reduction study of IL-17 and IL-23 biologics in psoriasis
2019-004230-42Phase 4Completed
- Sponsor
- Radboudumc
- Start
- Mar 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of secukinumab, ixekizumab, brodalumab, risankizumab, tildrakizumab and 1 more in plaque psoriasis and psoriasis (2 arms), sponsored by Radboudumc. Primary endpoint: Cumulative incidence of persistent flares. Started Mar 2020; status: completed.
02
Drugs
secukinumabixekizumabbrodalumabrisankizumabtildrakizumab
03
Conditions
plaque psoriasispsoriasis
Beyond the preview
Go deeper on 2019-004230-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004230-42.